Abstract
Hormone imbalance and female sexual dysfunction immensely affect perimenopausal female health and quality of life. Hormone therapy can improve female hormone deficiency, but long-term use increases the risk of cardiovascular diseases and cancer. Therefore, it is necessary to develop a novel effective treatment to achieve long-term improvement in female general and sexual health. This study reviewed factors affecting syndromes of female sexual dysfunction and its current therapy options. Next, the authors introduced research data on mesenchymal stromal cell/mesenchymal stem cell (MSC) therapy to treat female reproductive diseases, including Asherman’s syndrome, premature ovarian failure/primary ovarian insufficiency, and vaginal atrophy. Among adult tissue-derived MSCs, adipose tissue-derived stem cells (ASCs) have emerged as the most potent therapeutic cell therapy due to their abundant presence in the stromal vascular fraction of fat, high proliferation capacity, superior immunomodulation, and strong secretion profile of regenerative factors. Potential mechanisms and side effects of ASCs for the treatment of female sexual dysfunction will be discussed. Our phase I clinical trial has demonstrated the safety of autologous ASC therapy for women and men with sexual hormone deficiency. We designed the first randomized controlled crossover phase II trial to investigate the safety and efficacy of autologous ASCs to treat female sexual dysfunction in perimenopausal women. Here, we introduce the rationale, trial design, and methodology of this clinical study. Because aging and metabolic diseases negatively impact the bioactivity of adult-derived MSCs, this study will use ASCs cultured in physiological oxygen tension (5%) to cope with these challenges. A total of 130 perimenopausal women with sexual dysfunction will receive two intravenous infusions of autologous ASCs in a crossover design. The aims of the proposed study are to evaluate 1) the safety of cell infusion based on the frequency and severity of adverse events/serious adverse events during infusion and follow-up and 2) improvements in female sexual function assessed by the Female Sexual Function Index (FSFI), the Utian Quality of Life Scale (UQOL), and the levels of follicle-stimulating hormone (FSH) and estradiol. In addition, cellular aging biomarkers, including plasminogen activator inhibitor-1 (PAI-1), p16 and p21 expression in T cells and the inflammatory cytokine profile, will also be characterized. Overall, this study will provide essential insights into the effects and potential mechanisms of ASC therapy for perimenopausal women with sexual dysfunction. It also suggests direction and design strategies for future research.
Introduction
Adipose tissue is an important production site of female sex hormones outside the ovaries (Ahima and Flier 2000; Hetemäki et al., 2021). In premenstrual women, adipocytes express a high level of estrone and metabolic enzymes to convert this form into estrogen (Si et al., 2019). Adipose tissue is also an abundant source of mesenchymal stem/stromal cells (MSCs). These multipotent cells reside in the stromal vascular fraction of adipose tissue and represent a component of the vascular niche with an essential role in the regulation of angiogenesis as well as tissue repair upon injury (Lin et al., 2008; Panina et al., 2018). Adipose-derived stromal/stem cells (ASCs) are known as key players in adipogenesis (Matsushita and Dzau 2017; Munir et al., 2017; Q. Chen et al., 2016). Both MSC-based therapy and drugs controlling MSC maturation into white and brown fat have been studied to manage obesity (Jaber et al., 2021).
In regenerative medicine, ASCs represent a robust and potent therapeutic candidate that can be used directly after isolation or expanded on a large scale in vitro (Bateman et al., 2018; Kabat et al., 2020). Both autologous and allogeneic ASCs have been licensed for the treatment of several diseases, such as Alofisel to treat complex perianal fistulas in Crohn’s disease in the EU, Allosterm for bone regeneration in the United States, and QueenCell, Cupistem, and Adipocel to treat subcutaneous tissue defects and Crohn’s fistula in Korea (Najar et al., 2022). Furthermore, ASC therapy has been applied to treat other disorders, such as bone and cartilage degenerative diseases, ischemic disorders, cardiovascular diseases, neurological disorders, autoimmune diseases, wound healing, and skin burns (Si et al., 2019; Krawczenko and Klimczak 2022). In the case of female reproductive diseases, most experimental studies and clinical trials have used ASCs for patients with premature ovarian failure and Asherman syndrome (Zhao et al., 2019; Na and Kim 2020). ASCs were able to improve sex hormone levels and restore fertility in patients (Polonio et al., 2021). Studies in animal models also support clinical results demonstrating ASCs as a promising novel therapeutic opportunity for female infertility (L. Chen et al., 2018). This study reviews the mechanisms and outcomes of MSC therapy for female reproductive disorders. In addition, the authors introduce the study protocol of a to be initiated clinical trial: “evaluation of autologous ASC efficacy for the treatment of female sexual dysfunction: a randomized phase II crossover study”.
Female sexual dysfunction as a widespread distress
Female sexual dysfunction is highly prevalent–although it is not limited to–in aged women and widely impacts the health and quality of life of patients (Anastasiadis et al., 2002). The most common symptoms of female sexual dysfunction include diminished vaginal lubrication, pain during intercourse, lack of desire for sex, and difficulty in achieving orgasm (“American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology, 2019; Krakowsky and Grober 2018; Allahdadi et al., 2009). A survey in the United States showed that 43.1% of women reported having sexual problems, and 22.2% were diagnosed with sexually related distress based on the Female Sexual Distress Scale (FSDS) (Shifren et al., 2008). In four European countries, including France, Italy, Germany, and the UK, low sexual desire was the most frequent female sexual dysfunction, ranging from 21 to 36% depending on the country studied, and the prevalence was closely correlated with increasing age (Graziottin 2007). Between 70 and 80% of Finnish women aged 55 to 74 had decreased libido compared to 20% of those younger than 25 years (McCabe et al., 2016). Of note, menopause occurs in Caucasian and Asian women on average at age 51 (Boulet et al., 1994; Baber et al., 2016), and the deceased level of estrogens is associated with diverse physiological and emotional changes in postmenopausal women (Graziottin and Leiblum 2005). Along with the natural aging process, which is hallmarked by altered immune system functions, increased inflammation, and altered metabolism, the lack of sex hormones can further negatively impact women’s general and sexual health (Figure 1).
FIGURE 1
Many factors might influence female sexual dysfunction, including the endocrine system, medication side effects, overall health, and psychological and social life (Basson et al., 2001; Graziottin et al., 2006; Giraldi and Wåhlin-Jacobsen 2016). Age-related physical changes, such as a decrease in sex hormones, can directly cause sexual dysfunction (Davis and Tran 2001; R. Basson 2007; AlAwlaqi et al., 2017; McCoy and Davidson 1985). Several studies have demonstrated that an insufficient level of estrogen rather than testosterone is responsible for increased sexual distress during menopause (Dennerstein et al., 2002; Aziz et al., 2005; Gerber et al., 2005). Estrogen, especially estradiol, plays an important role in the development and regulation of female reproductive organs as well as the cardiovascular and cognitive system, bone integrity, and insulin sensitivity (Hall et al., 2001; Belgorosky et al., 2009; Findlay et al., 2010; Simpson and Santen 2015). Circulating estrogen is produced mainly by the ovaries and by the adrenal glands and placenta in smaller amounts in reproductive females (Hillier et al., 1994; J. Cui, Shen, and Li 2013). The estradiol level in serum drops after menopause, resulting in vaginal dryness and atrophy, reduced genital sensitivity upon stimuli and therefore lower sexual desire of middle-aged and older women (Bygdeman and Swahn 1996; Dennerstein et al., 2002; R. Basson 2007). Furthermore, a low level of estrogen will lead to reduced physiological needs, menstrual disorders, and difficulties in conceiving and nurturing the fetus (Nelson 2008; Gracia and Freeman 2018; Minkin 2019). Parallel to the change in estrogen, a gradual decline in testosterone belongs to a natural aging process of the body (Graziottin and Leiblum 2005). Testosterone is critical for sexual desire as well as sense of well-being in females (Davis and Tran 2001). Indeed, women with testosterone deficiency, most frequently observed in surgically menopausal patients, and those receiving antiandrogens reported low libido, reduced sexual interest and fatigue (Appelt and Strauss 1984; Adamopoulos et al., 1988; Bachmann 2002). In addition to decreased sex hormone levels, physical health conditions such as inflammatory, metabolic, and cardiovascular diseases also increase the risk of female sexual dysfunction (AlAwlaqi et al., 2017; Di Francesco et al., 2019; Lorenz 2019). A systematic review indicated that sexual dysfunction is common in patients with arthritis (Restoux et al., 2020). Patients with inflammatory bowel disease experience impaired sexuality depending on the disease severity (Timmer et al., 2008; de Silva et al., 2018; J. Zhang et al., 2022). Diabetes affects a wide range of patients’ health, including sexual activity. Many large studies have demonstrated an elevated sexual dysfunction prevalence among women with type 1 and type 2 diabetes (Enzlin et al., 2009; Nowosielski et al., 2010; Copeland et al., 2012; Shi et al., 2012; Elyasi et al., 2015). Hyperlipidemia, which is characterized by a pathogenic lipid profile and is known as a risk factor for vascular diseases, is linked to female sexual distress in all domains, including desire, arousal, lubrication, orgasm, satisfaction, and pain (Esposito et al., 2009; Martelli et al., 2012; Baldassarre et al., 2016). Data reporting a relationship between systemic arterial hypertension and sexual dysfunction in females remain controversial. While a significant correlation was observed in some studies (Doumas et al., 2006; Miner et al., 2012; De Franciscis et al., 2013; Nascimento et al., 2015), other studies reported no association between the diseases (Spatz et al., 2013; Foy et al., 2016). Overall, the data suggest that low serum sex hormone levels as well as disease-related conditions such as chronic inflammation, metabolic and cardiovascular diseases and persistent inflammation increase the risk of developing female sexual dysfunction.
Due to the complexity of the disorder, effective medical care for females with sexual dysfunction remains challenging. Estrogen replacement therapy is commonly prescribed to treat postmenopausal syndromes (Kovalevsky 2005; Simpson and Santen 2015; Stuenkel et al., 2015). Potential side effects of systemic and local use of estrogen include thrombosis, endometrial hyperplasia, stroke, and the development of breast and cervical cancer (Writing Group for the Women’s Health Initiative Investigators 2002; Wentzensen and Trabert 2015; Collaborative Group on Epidemiological Studies of Ovarian Cancer 2015). Moreover, the therapy negatively influences the serum testosterone concentration, leading to complications in sexual and general health, such as reduced libido and general sense of well-being, and/or increased muscle and bone loss (J. A. Simon 2002; Sarrel 2002). The use of androgen supplements for estradiol treatment was capable of reversing this effect (Davis et al., 1995; J. Simon et al., 1999; Shifren et al., 2000). Hence, combined therapy of estradiol and testosterone can be beneficial for the treatment of sexual dysfunction in menopausal women. However, long-term use of androgens might induce excessive hair growth in a male-like pattern (also known as hirsutism), acne, hair loss, decreased high-density lipoprotein levels, and hepatic toxicity (Abdallah and Simon 2007; Khera 2015). Flibanserin is the first FDA-approved drug to treat hypoactive sexual desire disorder, although there are still debates about its clinical benefit. The drug acts as a serotonin antagonist while enhancing the effect of dopamine to enhance the sexual response. In randomized trials, the treatment of women with hypoactive sexual disorder has shown modest efficacy compared to the control group (Jaspers et al., 2016; Lodise 2017). Adverse effects, including dizziness, sleepiness, nausea, and fatigue, were reported in these trials. Recently, the FDA approved bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (Mayer and Lynch 2020). The drug stimulates the neurological activity of the hypothalamic and limbic regions of the brain, probably via the dopamine signal to engage sexual activity (Pfaus et al., 2007). Although side effects appear mild to moderate with nausea, facial flushing, and headache, administration of the drug requires some effort, as it must be injected subcutaneously ca. 45 min prior to intercourse (Kingsberg et al., 2019). Despite the long history of searching for medication to treat female sexual dysfunction marked by the first use of estradiol in the 1940s, further research on novel therapy and the long-term safety of currently approved drugs remains essential, especially for those unsuitable for hormone replacement therapy.
MSC therapy for the treatment of experimental female reproductive disorders
A potential benefit of cell therapy in the management of reproductive diseases was first reported for women whose ovaries were damaged after chemotherapy and whose ovarian function and fertility were recovered (Sanders et al., 1996; Hershlag and Schuster 2002). Recently, MSC therapy, including ASCs, has emerged as a potential candidate to regenerate damaged tissues and rejuvenate organs. Many studies have demonstrated the efficacy of MSCs from various sources in the treatment of diseases related to reproductive function and hormone deficiency. In a postmenopausal rat model, human umbilical cord-derived MSC infusion restored estradiol and AMH levels while decreasing FSH levels in correlation with increased levels of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1), which play an important role in ovarian function (Jia Li B. et al., 2017). Human amniotic MSCs were able to restore AMH and estrogen levels in the ovaries of aging mice 1 week after stem cell injection (C. Ding et al., 2018a). In a rat model of Asherman’s syndrome, which is characterized by intrauterine adhesions due to the formation of scar tissue in the uterus, the administration of ASCs in combination with estrogen induced endometrial regeneration in treated animals (H. Sun et al., 2018).
An increasing number of studies have reported positive effects of MSC therapy on restoring ovarian function in premature ovarian failure (Zhao et al., 2019; Na and Kim 2020). Premature ovarian failure, also known as primary ovarian insufficiency, is defined as a loss of reproductive and hormonal functions of the ovaries in women before the age of 40 years. Premature ovarian failure results in a decline in women’s physical and mental health, such as amenorrhea, ovarian atrophy, sexual hypoactivity and infertility in young women (Beck-Peccoz and Persani 2006). In a rat model of chemotherapy-induced premature ovarian failure, BM-MSCs reduced luteinizing hormone (LH) and FSH and increased serum estradiol levels compared to the control group (Afifi and Reyad 2013). Placenta-derived MSCs restored serum estradiol, AMH, and FSH concentrations and recovered ovarian function in mice with premature ovarian failure (H. Zhang et al., 2018; Li et al., 2018). ASCs have also demonstrated promising potential to regenerate ovarian functions. Indeed, ASCs enhanced angiogenesis and recovered the number of follicles and corpus luteum defects in damaged ovaries (Terraciano et al., 2014; M. Sun et al., 2013). Improved serum estradiol levels and increased pregnancy rates have also been reported in ASC-transplanted mice (Fouad et al., 2016). Another approach was a combined injection of ASCs and collagen scaffolds. The treated group showed a significant increase in estradiol levels, granulosa cell proliferation, and both mating and pregnancy rates compared to the PBS control group (Su et al., 2016). A study in rabbits showed that MSC therapy improves ovarian function through direct differentiation into specialized cells in the ovary or secretion of VEGF growth factor, which helps ovary regeneration (Abd-Allah et al., 2013).
Recently, MSCs have been investigated for the treatment of vaginal atrophy. The disease affects more than half of menopausal women due to decreased estrogen levels resulting in thinning of vaginal epithelium and reduced local blood flow. As a result, women with vaginal atrophy often suffer from vaginal dryness, itching, burning, and pain when urinating and during intercourse (Naumova and Castelo-Branco 2018). ASCs and bone marrow-derived MSCs were able to improve epithelial thickness in a menopause rat model of vaginal atrophy with superior therapeutic effects in the former group (Kasap et al., 2019). The expression of estrogen receptor, VEGF and its receptor was increased in vaginal epithelium and connective tissue after MSC administration (Kasap et al., 2019). Zhang et al. performed in situ injection of umbilical cord-derived MSCs to repair fragile vaginal tissue in an ovariectomized rhesus macaque model (Zhang et al., 2021). The treatment successfully induced the formation of extracellular matrix fibers, especially collagen I and elastin, and smooth muscle in the vagina. Furthermore, microvascular density was increased along with more pronounced VEGF expression in the treated group (Zhang et al., 2021).
Overall, preclinical results support the use of MSCs to overcome menopausal symptoms and restore the function of the ovaries and uterus. MSC therapy might add an alternative therapeutic option to the standard hormone replacement therapy for the treatment of female reproductive diseases.
MSC therapy for female reproductive disorders: Clinical trials
Clinical trials investigating MSC therapy in the landscape of female reproductive disorders are still in an early stage (Takahashi et al., 2021; Zhao et al., 2019; L. Chen et al., 2018). Some studies have performed stem cell injection into the uterus followed by hormone replacement therapy for women with severe Asherman syndrome or endometrial atrophy (Cao et al., 2018; Lee et al., 2020; Ma et al., 2020; Singh et al., 2020). Overall, they showed superior endometrial regeneration and higher pregnancy rates after treatment. Menstruation was restored in amenorrhea women and prolonged or increased in menstrual amounts in the other patients (Lee et al., 2020; Ma et al., 2020; Singh et al., 2020).
Furthermore, MSC therapy has been investigated for the treatment of primary ovarian failure in phase I and II trials showing improved follicular development after intraovarian injection of MSCs (L. Ding et al., 2018b; Edessy et al., 2016; Gupta et al., 2018; Herraiz et al., 2018; Igboeli et al., 2020; Mashayekhi et al., 2021; Mohamed et al., 2018; Yan et al., 2020). Estradiol was elevated after umbilical cord and bone marrow-derived MSC administration (Igboeli et al., 2020; L. Ding et al., 2018b). Reduced menopausal symptoms and return of menstruation were also commonly reported (Edessy et al., 2016; Igboeli et al., 2020; Mashayekhi et al., 2021). Two of 14 umbilical cord-derived MSC-injected patients were pregnant after years of infertility (L. Ding et al., 2018b). Gupta reported a case of a perimenopausal woman with primary ovarian failure who delivered a healthy baby after receiving autologous bone marrow-derived MSCs (Gupta et al., 2018). Mashayekhi et al. infused autologous ASCs into nine women with primary ovarian failure at three different doses of 5 × 106, 10 × 106, or 15 × 106 cells/kg body weight (Mashayekhi et al., 2021). During the 24-months follow-up, no side effects or complications occurred. In the group receiving the highest dose, two of three patients resumed menstruation after 2 months, and menstruation was observed again 1 month after infusion in two of six patients in the other groups. Serum FSH levels decreased to less than 25 IU/l in four patients, while ovarian size did not differ between the groups (Mashayekhi et al., 2021). Recently, we performed an intravenous infusion of ASCs in 16 women with sexual hormone deficiency at a dose of 1 × 106/kg body weight and followed up for 12 months after the infusion (Nguyen LT. et al., 2021). The study showed that no serious adverse events or adverse events occurred in the patients. Women reported satisfaction with their sex lives; however, there was no significant change in AMH, FSH and estradiol levels (Nguyen T. et al., 2021).
Because these studies were performed in only small numbers of patients without control groups, the power of their results remains limited. Therefore, larger randomized controlled trials will be necessary to investigate the safety and potential efficacy of MSC-based therapy in the management of female reproductive disorders.
Potential mechanisms of ASCs for the treatment of female sexual dysfunction
ASCs might act in different ways to improve sexual dysfunction in premenopausal women (Figure 2).
FIGURE 2
Homing, retention, and differentiation
GFP-labeled ASCs resided in the ovarian interstitial tissue surrounding oocytes 7 days after in situ transplantation (Terraciano et al., 2014). In concordance with this observation, GFP+ ASCs were retained in ovaries 14 days after injection, but most of them disappeared after 4 weeks (Su et al., 2016), while Sun et al. was able to detect GFP + ASCs in ovaries 1 month after both intravenous and in situ injection (M. Sun et al., 2013). The cells did not differentiate into oocytes or granulosa cells but rather took part in the microenvironment of these cells. Indeed, ASCs gave rise to the basal lamina and the theca layer to support granulosa cell function in a rat model of primary ovarian failure (Su et al., 2016). Similarly, ASCs and ASCs on collagen scaffolds differentiated into epithelial and stromal cells of the endometrium in an Asherman’s syndrome model with a longer retention time in the latter group (H. Sun et al., 2018). ASCs were also able to be differentiated in vitro into vascular endothelial cells when cultured with umbilical vein endothelial cells (Fischer et al., 2009; Bekhite et al., 2014).
Elevated follicle numbers and estradiol levels
Viable follicles increased in the ASC-injected group compared to the control, but estradiol concentration in serum was similar between the two groups (Terraciano et al., 2014). Fouad et al. reported that ASCs induced the development of ovarian follicles and yellow bodies in concordance with higher serum estradiol levels and reduced FSH (Fouad et al., 2016). Injection of ASCs with collagen scaffolds resulted in a better estrous cycle and an increase in estradiol (Su et al., 2016).
Paracrine effects of ASCs to promote angiogenesis and cell growth
ASCs signal to other cells through the synergistic action of soluble proteins and extracellular vesicles. ASCs are superior sources of growth factors such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor 2 (FGF-2), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), angiopoietin-1 and -2 (Ang-1 and Ang-2), brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and insulin-like growth factor (IGF) (Rehman et al., 2004; Sadat et al., 2007; Kingham et al., 2014; Dabrowski et al., 2017; Y.-H. An et al., 2021; Jiao et al., 2021; Ngo et al., 2021; Sumarwoto et al., 2021). These factors mediate ASCs to promote angiogenesis (Jiao et al., 2021; Krawczenko and Klimczak 2022), cell survival (Rehman et al., 2004), cell proliferation (Jiao et al., 2021), and wound healing processes (Y.-H. An et al., 2021) in many disease models. The role of growth factors produced in the reproductive system was reviewed previously, suggesting a complex regulated network of signaling pathways orchestrated in ovarian development and function (Evron et al., 2015). IGF signaling is essential for follicular development (Giudice 1992), in which IGF-1 stimulates the proliferation of human granulosa cells and induces estradiol and progesterone production in the ovary (Zhou et al., 2013). It also cooperates with FSH to regulate germ cell differentiation (Zhou et al., 2013). FGF-2 accompanied by progesterone maintains the survival of granulosa cells and epithelial cells on the surface of ovaries (Trolice et al., 1997; Peluso and Pappalardo 1999). FGF-2 and EGF can stimulate granulosa cell proliferation (Gospodarowicz and Hugh 1979). VEGF and neurotrophic factors, such as BDNF and GDNF, also protect follicular cells from apoptosis and therefore regulate oocyte maturation (Shin et al., 2006; Linher-Melville and Li 2013). VEGF plays a multipotent role during follicular development. Inhibition of VEGF-A interfered with theca and granulosa cell proliferation, diminished follicular angiogenesis, disrupted ovulation, and led to miscarriage (Wulff et al., 2001; Fraser et al., 2010). In a mouse model of vaginal atrophy, ASC administration induced increased expression of VEGF and its receptor in both connective tissue and the epithelial layer of the vagina in correlation with a higher anti-apoptotic factor bcl2 and reduced epithelial damage (Kasap et al., 2019).
In addition to soluble proteins, extracellular vesicles are another form of cell communication (Mittelbrunn and Sánchez-Madrid 2012; Turturici et al., 2014). Their cargos include lipids, growth factors, cytokines, membrane proteins, and genetic materials, especially microRNAs (Zhang et al., 2019; Wei et al., 2021). Mitchel et al. identified more than 20,000 miRNA sequences of the ASC secretome and extracellular vesicles, of which half of the target mRNAs were linked to signal transduction, response to stress, and regulation of cell differentiation and proliferation (Mitchell et al., 2019). The proangiogenic let-7 family, miR16, miR-23a, and miR-23b were highly expressed in their analysis (Landskroner-Eiger et al., 2013; Mitchell et al., 2019). Overexpression of mRNA-21, which is a key regulator of cancer angiogenesis, enhanced vascularization by upregulating HIF-1α, VEGF, Akt and Erk signaling (Y. An et al., 2019). Moreover, miR-21 activated the PI3K/AKT signaling pathway to promote cell migration and proliferation during the wound healing process (C. Yang et al., 2020).
Immunomodulatory potential of ASCs
ASCs demonstrate a superior immunomodulatory capacity compared to MSCs from other tissue origins, such as bone marrow, dental pulp, and umbilical cord (Melief et al., 2013; Ribeiro et al., 2013; Mattar and Bieback 2015). The cells regulate the innate and adaptive immune systems through both direct cell‒cell contact and secretion of cytokines and other soluble factors (Al-Ghadban and Bunnell 2020; Ceccarelli et al., 2020). ASCs secrete many anti-inflammatory factors, including prostaglandin E2 (PGE2), indoleamine-2,3-dioxygenase (IDO), transforming growth factor-beta (TGF-β), and programmed cell death ligand (PD-L1) (J.-H. An et al., 2018; Bulur and Dietz 2018; Cho et al., 2015; Eljaafari et al., 2021; Kawada-Horitani et al., 2022; Mckinnirey et al., 2021; Yañez et al., 2010; Zheng et al., 2017). The cell also produces highly anti-inflammatory miRNAs, especially the let7 family, miR-26a-5p and miR-16-5p, which are involved in immune cell regulation (Mitchell et al., 2019; Ragni et al., 2019).
ASCs inhibited Th1-cell proliferation and downregulated the expression of proinflammatory cytokines such as TNF-α, IFN-γ, and IL-12, while they stimulated regulatory T-cell differentiation (Yañez et al., 2006; Gonzalez-Rey et al., 2010; Engela et al., 2013). ASCs also have multiple effects on B cells, as they induce the quiescence of B cells, inhibit the formation of plasmablasts and activate IL-10-expressing regulatory B cells (Franquesa et al., 2015; Peng et al., 2015). Consequently, IgM, IgG, and IgA production was significantly impaired in the presence of ASCs (Corcione et al., 2006). Therefore, ASCs have been successfully applied to treat graft-versus-host disease, which is caused by the cytotoxicity of donor-derived T cells against recipient and autoimmune diseases and is mediated by B-cell misdirection toward the patient’s own cells (González et al., 2009; Peng et al., 2015; Panés et al., 2016; Fernández et al., 2018; Castro et al., 2020).
ASCs can shift macrophages from the M1 phenotype to the M2 phenotype via their secretomes, such as PGE2, IL6, TSG-6, and miR-451 (Song et al., 2017; C.-Y. Yang et al., 2021; R. Li et al., 2022; Yuan et al., 2022). M2 macrophages secrete immunosuppressive and anti-inflammatory cytokines IL-10 and TSG-6 to modulate immune reactions and activate tissue repair (Kim and Hematti 2009; Heo, Choi, and Kim 2019; R. Li et al., 2022). Similar to macrophages, dendritic cells are also a target of ASCs. A coculture of these cells resulted in blockade of dendritic cell maturation and changed them into an anti-inflammatory phenotype with enhanced phagocytosis (Anderson et al., 2017; Ortiz-Virumbrales et al., 2020). ASCs have been shown to be superior in suppressing dendritic cells compared to their bone marrow-derived counterparts (Ivanova-Todorova et al., 2009; Zaza et al., 2019). On the other hand, the interaction between MSCs, including ASCs, and NK cells is complex and remains controversial depending on the coculture conditions and prestimulation of NK cells. There are studies showing that ASCs were able to alter NK functions (DelaRosa et al., 2012; Najar et al., 2019). However, they are less potent in inhibiting NK-cell cytotoxic activity than bone marrow-derived MSCs (Valencia et al., 2016; Najar et al., 2019).
Study protocol for a randomized controlled phase II clinical trial to investigate the therapeutic potential and mechanisms of autologous ASCs in female sexual dysfunction
This is a randomized controlled phase II clinical trial with a crossover design to evaluate the safety and potential efficacy of autologous ASC therapy to treat sexual dysfunction in females. A total of 130 female patients with sexual dysfunction will be recruited at the Regenerative Medicine Department at Vinmec Times City International Hospital, Hanoi, Vietnam, between September 2022 and December 2024. The inclusion and exclusion criteria of the study are presented in detail in the supplementary information. Enrolled patients will be randomly divided into two groups (Figure 3). Patients in group A will receive two infusions of autologous ASCs at day 0 and day 90 ± 7, while those in group B will be followed-up for 180 ± 14 days and then receive two infusions of autologous ASCs at day 180 ± 14 and day 270 ± 14.
FIGURE 3
Autologous ASCs used in this study were harvested from autologous fat tissue through an enzyme method and expanded using our in-house optimized serum-free and xeno-free culture under a physiological oxygen concentration of 5% as described in the supplementary information (Hoang et al., 2020). For clinical use, cells at passage 3 will be harvested in 100 ml Ringer’s lactate. Therapeutic ASC products must pass the following releasing criteria: 1) negative for bacteria, fungi and mycoplasma; 2) more than 90% viability; 3) expression of more than 95% positivity for CD105, CD73, and CD90 and less than 2% positivity for CD45, CD34, CD11b, CD19, and HLA-DR; and 4) endotoxin < 5 EU/kg. The patient will be infused with 1 × 106 cells/kg body weight within 60 min via the intravenous route.
The patients will be monitored within 12 months after the first cell infusion (Table 1). Here, the authors use a comprehensive study plan to evaluate the efficacy of autologous ASC therapy in the management of female sexual dysfunction through three levels: 1) self-assessment questionnaires; 2) female sex hormones; and 3) biomarkers of inflammation and cellular senescence.
TABLE 1
| Study procedure | Prescreening (If applicable) | Screening phase* | Baseline | Day 30 ± 3 | Day 90 ± 7 | Day 180 ± 14 | Day 270 ± 14 | Day 365 ± 14 | Day 365 ± 14 | Day 545 ± 14 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASC Infusion | ||||||||||
| Group A |  | | ||||||||
| Group B | | | ||||||||
| Concomitant therapy** | | | | | | |||||
| Informed consent | | |||||||||
| Inclusion and exclusion criteria | | |||||||||
| Demographic information | | | | |||||||
| Patient’s medical reports | | | | | | | | | | |
| Physical examination | | | | | | | | | | |
| Female sex hormone evaluation (FSH, E2) | | | | | | | | | | |
| Cytokines and aging biomarkers evaluation# | | | | | | |||||
| Hematology analysis*** | | | | | | | | | | |
| Infectious disease examination/test## | | | | |||||||
| Thrombotic analysis§ | | | | | | | | | ||
| Quality of life evaluation† | | | | | | | | | | |
| Adverse events (AEs/SAEs) evaluation | | | | | | | | | ||
| Monitoring of mortality/complications | | | | | | | | | ||
| Blood sample for molecular and cellular analyses of sexual function impairment | | | | | | | | |
Study timeline and clinical procedures during the trial.
Notes: ASC, autologous adipose-derived mesenchymal stem/stromal cell, AEs, adverse events; SAEs = serious adverse events; FSH, Follicle-Stimulating Hormone, E2 = Estradiol Hormones, FSFI, Female Sexual Function index; HBV, hepatitis B virus, HIV, human immunodeficiency virus; UQOL , Utian quality of life Scale.
*If the results of the screening phase for ASC, groups are within 30 days of ASC, administration, they will be automatically considered as the baseline level.
**The concomitant therapy administered to both groups included Hightamin, total Calcium, Bioflex, Cic-Zinc.
§The thrombotic analysis included measurement of the D-dimer, fibrinogen, prothrombin, thrombin, and APTT, levels prior to ASC, administration and 24-h post-administration.
***The hematological analysis included measurements of the white blood cell count, platelet count, red blood cell count, hemoglobin, and percentages of lymphocytes, neutrophils, monocytes, eosinophils, basophils, C-reactive protein, pro-BNP, and troponin-T.
#Blood samples will be collected for cellular and molecular analysis, including analyses of cytokines, chemokines, and aging biomarkers in the patient’s plasma: TNFa, IFN-γ, IL1, IL-6, IL-8, IL-4, IL-10, and IDO, plasminogen activator inhibitor-1 (PAI-1), p16 and p21 expression.
##Infectious diseases include hepatitis, syphilis, HIV, HBV, and tuberculosis.
† The quality of life evaluation includes the self-assessment questionnaires: FSFI and UQOL.
The improvement of sexual function and overall quality of life will be assessed through the FSFI and the Utian Quality of Life Scale (UQOL). The FSFI is a self-assessment questionnaire to quantify female sexual function. The FSFI index has high to very high reliability and repeatability (Rosen et al., 2000; Meston 2003; Wiegel et al., 2005), and a score of ≤ 26.55 is classified only as female sexual dysfunction (FSD) (Wiegel et al., 2005. The UQOL is a modern instrument to measure the quality of life of menopausal women (Utian et al., 2018). It has been clinically proven effective and has been applied across many countries (Abay and Kaplan 2016; Balanian et al., 2020; Moravcova et al., 2022).
Furthermore, changes in the levels of FSH and estradiol will be examined. FSH stimulates granulosa cells in ovarian follicles to synthesize aromatase, which converts androgens produced by thecal cells to estradiol (Steinkampf et al., 1987; Hillier et al., 1994). Estradiol is a steroid hormone associated with the female reproductive organs and is responsible for the development of female sexual characteristics (Findlay et al., 2010). Elevated FSH and decreased estradiol concentrations are responsible for menopausal symptoms, including decreased functions of reproductive organs (Mason 1976). Therefore, levels of FSH and estradiol would reflect female sexual health in general and during the perimenopausal period.
To study ASC effects at the cellular and molecular levels, the serum concentrations of cytokines (TNFa, IFN-γ, IL1, IL-6, IL-8, IL-4, IL-10, IDO) will be quantified. In addition, the expression of senescence biomarkers, including plasminogen activator inhibitor-1 (PAI-1), p16, and p21, is also of interest. Since chronic inflammation and the natural aging process increase the incidence of female sexual dysfunction, the analysis might provide a hint for the mechanisms of action of cell therapy.
Rationales of the crossover design of the proposed clinical trial
A randomized crossover trial is a prospective study in which participants received two or more sequential interventions in a random order, often separated by a washout period (Senn 2002). It allocates participants to different treatments over two or more periods, while in a parallel trial, participants are randomized to the same intervention over a single period (Mills et al., 2009).
In this study, we choose a two-sequence crossover design since the AB/BA design has some advantages over the parallel-group design. First, the two-sequence crossover design is robust and applicable when there is considerable between-patient variability and less within-patient variability (Gewandter et al., 2019). Second, fewer participants needed to be recruited for similar statistical power (Senn 2002; Chow and Liu 2009; Wellek and Blettner 2012). A crossover trial is a “within-subject” study design where each participant acts as his or her control (Sedgwick 2014). Crossover trials may offer more precise intervention effect estimates than parallel trials because they would remove any biological and methodological variation (Mills et al., 2009).
However, the crossover design also has some weaknesses. The time to conduct a crossover trial is longer than that to conduct a parallel-group trial. Moreover, the cross-sectional design may even induce bias, such as confounding, which can also arise from sequential randomization of an insufficient number of clusters (Goldstein et al., 2018) or the effects of attrition (Moerbeek 2020). In addition, proper statistical methods are required to analyze crossover trials to reduce treatment effects, carryover effects, and period effects (Nason and Dean 2010; Wellek and Blettner 2012; Sturdevant and Lumley 2021).
Discussion
Potential side effects of ASC therapy in general medicine including female sexual dysfunction
A meta-analysis investigated adverse events after MSC administration based on 62 prospective studies with the longest follow-up of 5 years (Wang et al., 2021). There was no connection between the therapy and cancer and mortality incidence. The most common major side effect was transient fever, which developed within 48 h after cell administration, followed by administration site adverse events such as bleeding, swelling, pain, itching and infection at the injection site. Minor side effects that were associated with MSC therapy included sleeplessness, fatigue, and constipation. Other events, such as seizure, vomiting, anemia, and nausea, were significantly associated with the therapy. Moreover, AD-MSCs more frequently caused headache and dizziness than bone marrow-derived MSCs (Wang et al., 2021). An update of the largest phase 3 randomized, double-blind control trial investigating the safety and efficacy of a single local administration of allogenic ASCs (Cx601) in patients with Crohn’s disease and perianal fistulas was reported (Panés et al., 2018). Although the treatment group experienced more frequent serious treatment-emergent adverse events during the 52-weeks follow-up than the control group (24,3% versus 20,6%, respectively), treatment-related serious events were comparable (6.8% versus 6.9%, respectively). The events included anal abscess/fistula in the treatment group and anal abscess/fistula, proctalgia, anal inflammation, and liver abscess in the control group (Panés et al., 2018).
The administration of allogenic MSCs might trigger immune reactions and immune rejection. This could be a cause of transient fever observed in patients after treatment (Wang et al., 2021). On the other hand, because ASCs express only low levels of major histocompatibility complex (MHC) class I molecules and are absent in MHC class II and costimulatory molecules, including CD40, CD80, and CD86, their immunogenicity remains low (L. Cui et al., 2007). Their strong immunosuppressive capacity further favors these cells to escape the host immune system (Yañez et al., 2006). In the Cx601 phase trial, no immune reactions or adverse events related to the development of donor-specific antibodies were observed. On the other hand, the ASC-treated group had a higher risk of developing IgG HLA class I antibodies, with a rise from 16% at baseline to 34% at week 12, in contrast to no change in the control group. The presence of donor-specific antibodies did not correlate with treatment outcome (Panés et al., 2016).
ASCs might activate coagulation when exposed to blood and increase the risk of thrombosis in patients undergoing stem cell therapy (Jung et al., 2013). Pulmonary embolism and infarct in the right lung were observed in a patient after being intravenously infused with three doses of autologous ASCs to treat the cervical herniated intervertebral disc. His parents, who received a similar therapy for knee osteoarthritis, also developed multiple embolisms in both pulmonary artery branches with right pleural effusion (Jung et al., 2013). The use of anticoagulants such as heparin and EDTA is recommended to prevent thrombogenesis (Liao et al., 2017; Moll et al., 2019).
A link between ASC therapy and tumorigenesis is still under investigation. Preclinical data suggest that ASCs can activate pathways involved in tumor formation and progression (Sabol et al., 2019). In most scenarios, ASCs interacted with the tumor microenvironment and mediated cell growth, metastasis, and chemoresistance of tumor cells in experimental breast, ovarian, cervical cancers, etc. (Zhang et al., 2015; Goto et al., 2019; Castro-Oropeza et al., 2020). However, clinical data supporting a connection between MSC treatment and tumor development are still lacking. In patients with hematologic malignancy, cotransplantation of bone marrow-derived MSCs with hematopoietic stem cells reduced graft-versus-host disease severity; however, it was associated with a higher relapse rate and increased patient mortality over a 3-year observation period (Ning et al., 2008). As a balance between graft-versus-leukemia and graft-versus-host reactions is required for a durable response of transplant patients, it remains unclear whether the disease recurrence was due to lower anti-leukemia activity of graft-derived T cells or MSC-induced leukemia stimulatory effects (Munker et al., 2004; Munker and Kolb., 2006).
Overall, clinical data suggest that ASC therapy is well tolerated with considerable side effects. However, long-term observations, especially in terms of tumorigenesis and the identification of risk factors/risk populations, remain elusive.
Using autologous versus allogenic ASCs: pros and contras
MSCs are suitable both in an autologous and an allogenic setting. Autologous cell transplantation is generally safer. There is no concern of infectious disease transmission and host versus graft incompatibility (Kot et al., 2019). Although MSCs express only a limited level of MHC class I and lack MHC class II and its cofactors (Samadi et al., 2021; J. Chen J-m et al., 2021), inflammatory reactions, graft rejection, and the development of graft-versus-host disease have been reported in animal models (Poncelet et al., 2007; Pezzanite et al., 2015; Owens et al., 2016). The choices between autologous versus allogenic cells often depend on the disease background, availability of cells (and donors), cost and window of delivery. Many factors can negatively impact MSC quality. Cells exhibit altered cellular functions leading to decreased regenerative bioactivity with increasing age (Peffers et al., 2016; Marędziak et al., 2016; Y.-H. K. Yang 2018). In addition, the authors have demonstrated that long-term type II diabetes mellitus could induce remarkable changes in mtDNA genetic profiles and negatively interfere with cell metabolism and bioactivity (Nguyen T. et al., 2021). On the other hand, potential genetic changes in the reproductive system need to be considered when allogenic cells are applied for the management of reproductive health (X. Chen et al., 2021b). Thus, challenges such as the maintenance of healthy MSC sources and boosting of their potency remain to be addressed in the case of autologous cell therapy, while immune reactions, graft rejection, and ethical concerns are of interest for allogenic use.
Enhancing the therapeutic activity of ASCs via hypoxic culture conditions
Physioxia (also known as hypoxia compared to the ambient oxygen concentration of the atmosphere) is a promising strategy to accelerate MSC functions both in vitro and in vivo. Under this condition, MSCs maintained a longer undifferentiated state (Basciano et al., 2011) and a longer proliferative lifespan before reaching senescence (Grayson et al., 2006). Furthermore, physioxia enhances MSC secretion of proangiogenic factors such as VEGF, IGF, HGF, and bFGF, as well as the immunomodulatory molecule TGF-β (Kinnaird. et al., 2004; Crisostomo et al., 2008; Ranganath et al., 2012; Noronha et al., 2019). In animal models, physioxia-cultured human MSCs demonstrated enhanced in vivo survival (Beegle et al., 2015). Physioxia successfully boosted MSC potencies in the treatment of ischemia (Han et al., 2016; Noronha et al., 2019) and lung damage induced by radiation or bleomycin (Lan et al., 2015; B. Li J. et al., 2017) compared to those cultured in ambient oxygen concentration. Thus, physioxia culture might improve the therapeutic potential of MSCs. However, implementation of physioxia culture in clinical settings remain to be investigated.
Summary
ASCs are a potent candidate for cell therapy with high growth factor secretion activity and superior immunomodulatory capacity. The side effects of ASC therapy are manageable, and there was no connection between the treatment and incidence of cancer and mortality in treated patients. However, longer follow-ups are required to study late events, especially in tumor formation and progression. ASC therapy for female reproductive diseases has been investigated preclinically and in some phase I clinical trials, suggesting a potential activity of ASCs in female sexual dysfunction. Based on our current knowledge about the benefits and challenges of ASCs, the authors have introduced the design of our phase II trial to study the safety and efficacy of autologous ASCs in the management of sexual dysfunction in perimenopausal women. The results of the proposed study will provide profound insight into MSC actions in this disease. It might also encourage a transition of MSC culture from high to physiological oxygen conditions in future research.
Statements
Author contributions
Conception and design of the study: VTH, HPN, VHN, TSTN, and NTL. Literature review: VTH, HPN, VHN, MDH, TSTN, NTL. Drafting or revising the manuscript: VTH, HPN, VHN, MDH, TSTN, and NTL. All authors have approved the final article.
Funding
The clinical trial will be funded by Vingroup research grants (project no. ISC.21.73). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Acknowledgments
The authors would like to thank all patients involved in the study for their trust, understanding, and willingness. We thank our collaborating clinicians and scientists at the Vinmec Health Care System for participating in this study. Figure 2 was created with BioRender.com. The manuscript was edited using AJE Digital Editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.956274/full#supplementary-material
References
1
AbayH.KaplanS. (2016). Validation and reliability of the Turkish utian quality-of-life scale in postmenopausal women. Menopause23 (4), 425–432. 10.1097/GME.0000000000000554
2
Abd-AllahH.ShalabyS. M.PashaH. F.S El-ShalA.RaafatN.SherenM.et al (2013). Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. Cytotherapy15 (1), 64–75. 10.1016/j.jcyt.2012.08.001
3
AbdallahR. T.SimonJ. A. (2007). Testosterone therapy in women: Its role in the management of hypoactive sexual desire disorder. Int. J. Impot. Res.19 (5), 458–463. 10.1038/sj.ijir.3901558
4
AdamopoulosD. A.KampyliS.GeorgiacodisF.,(1988). Effects of antiandrogen-estrogen treatment on sexual and endocrine parameters in hirsute women. Archives Sex. Behav.17 (5), 421–429. 10.1007/BF01542482
5
AfifiN. M.ReyadO. N. (2013). Role of mesenchymal stem cell therapy in restoring ovarian function in a rat model of chemotherapy-induced ovarian failure. Egypt. J. Histology36 (1), 114–126. 10.1097/01.EHX.0000423979.18253.10
6
AhimaR. S.FlierS. (2000). Adipose tissue as an endocrine organ. Trends Endocrinol. Metabolism11 (8), 327–332. 10.1016/S1043-2760(00)00301-5
7
Al-GhadbanS.BunnellB. A. (2020). Adipose tissue-derived stem cells: Immunomodulatory effects and therapeutic potential. Physiology35 (2), 125–133. 10.1152/physiol.00021.2019
8
AlAwlaqiA.AmorH.MohamedE. (2017). Role of hormones in hypoactive sexual desire disorder and current treatment. J. Turkish-German Gynecol. Assoc.18 (4), 210–218. 10.4274/jtgga.2017.0071
9
AllahdadiK.TostesR.WebbR. (2009). Female sexual dysfunction: Therapeutic options and experimental challenges. Cardiovasc. Hematological Agents Med. Chem.7 (4), 260–269. 10.2174/187152509789541882
10
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology (2019). Female sexual dysfunction: ACOG Practice bulletin clinical management guidelines for obstetrician-gynecologists, number 213. Obstetrics Gynecol.134, e1–18. 10.1097/AOG.0000000000003324
11
AnJ-H.SongW-J.LiQ.JungY-C.YounH-Y. (2018). Prostaglandin E2 secreted from feline adipose tissue-derived mesenchymal stem cells alleviate DSS-induced colitis by increasing regulatory T cells in mice. BMC Veterinary Res.14 (1), 354. 10.1186/s12917-018-1684-9
12
AnY.KimD. H.LeeE.LeeD.ParkM. J.KoJ.et al (2021). High-efficient production of adipose-derived stem cell (ADSC) secretome through maturation process and its non-scarring wound healing applications. Front. Bioeng. Biotechnol.9 (6), 681501. 10.3389/fbioe.2021.681501
13
AnY.ZhaoJ.NieF.QinZ.XueH.WangG.et al (2019). Exosomes from adipose-derived stem cells (ADSCs) overexpressing MiR-21 promote vascularization of endothelial cells. Sci. Rep.9 (1), 12861. 10.1038/s41598-019-49339-y
14
AnastasiadisA.DavisA. R.SalomonL.BurchardtM.ShabsighR. (2002). Hormonal factors in female sexual dysfunction. Curr. Opin. Urology12 (6), 503–507. 10.1097/00042307-200211000-00011
15
AndersonP.Gonzalez-ReyE.O’ValleF.MartinF.Javier OliverF.DelgadoM. (2017). Allogeneic adipose-derived mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by regulating self-reactive T cell responses and dendritic cell function. Stem Cells Int., 1–15. 10.1155/2017/2389753
16
AppeltH.StraussB. (1984). Effects of antiandrogen treatment on the sexuality of women with hyperandrogenism. Psychotherapy Psychosomatics42 (1–4), 177–181. 10.1159/000287842
17
AzizA.BrännströmM.BergquistC.SilfverstolpeG. (2005). Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil. Steril.83 (4), 1021–1028. 10.1016/j.fertnstert.2004.12.008
18
BaberR. J.PanayN.FentonA. (2016). 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric19 (2), 109–150. 10.3109/13697137.2015.1129166
19
BachmannG. A. 2002. “The hypoandrogenic woman: Pathophysiologic Overview.” Fertil. Steril.77 (4): 72–76. 10.1016/S0015-0282(02)03003-0
20
BalanianS.FallahzadehH.MohammadA. M. (2020). Validity and reliability of the Persian version of the utian quality of life scale (UQOL). J. Biostat. Epidemiol. 10.18502/jbe.v5i4.3872
21
BaldassarreM.AlvisiS.ManciniI.MoscatielloS.MarchesiniG.SeracchioliR.et al (2016). Impaired lipid profile is a risk factor for the development of sexual dysfunction in women. J. Sex. Med.13 (1), 46–54. 10.1016/j.jsxm.2015.11.005
22
BascianoL.NemosC.BernardF.de IslaN.de CarvalhoM.TranN.et al (2011). Long term culture of mesenchymal stem cells in hypoxia promotes a genetic program maintaining their undifferentiated and multipotent status. BMC Cell Biol.12 (1), 12. 10.1186/1471-2121-12-12
23
BassonR.BermanJ.BurnettA.LeonardD.FergusonD.JeanF.et al (2001). Report of the international consensus development conference on female sexual dysfunction: Definitions and classifications. J. Sex Marital Ther.27 (2), 83–94. 10.1080/00926230152051707
24
BassonR. (2007). Hormones and sexuality: Current complexities and future directions. Maturitas57 (1), 66–70. 10.1016/j.maturitas.2007.02.018
25
BatemanM. E.StrongA. L.GimbleJ. M.BunnellB. A. (2018). Concise review: Using fat to fight disease: A systematic review of nonhomologous adipose-derived stromal/stem cell therapies: Using fat to fight disease. STEM CELLS36 (9), 1311–1328. 10.1002/stem.2847
26
Beck-PeccozP.PersaniL. (2006). Premature ovarian failure. Orphanet J. Rare Dis.1 (1), 9. 10.1186/1750-1172-1-9
27
BeegleJ.LakatosK.KalomoirisS.StewartH.Rivkah IsseroffR.NoltaJan A.et al (2015). Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. STEM CELLS33 (6), 1818–1828. 10.1002/stem.1976
28
BekhiteM. M.FinkensieperA.RebhanJ. (2014). Hypoxia, leptin, and vascular endothelial growth factor stimulate vascular endothelial cell differentiation of human adipose tissue-derived stem cells. Stem Cells Dev.23 (4), 333–351. 10.1089/scd.2013.0268
29
BelgoroskyA.GuercioG.PepeC.SaracoN.RivarolaM. A. (2009). Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Hormone Res. Paediatr.72 (6), 321–330. 10.1159/000249159
30
BouletM. J.OddensB. J.LehertP.VemerH. M.VisserA. (1994). Climacteric and menopause in seven south-east asian countries. Maturitas19 (3), 157–176. 10.1016/0378-5122(94)90068-X
31
BulurP.DietzA. (2018). Secretion of indoleamine 2-3 deoxygenase by adipose derived mesenchymal stromal cells as a biomarker for immune suppressive capacity. Cytotherapy20 (5), S35. 10.1016/j.jcyt.2018.02.086
32
BygdemanM.SwahnM. L. (1996). Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas23 (3), 259–263. 10.1016/0378-5122(95)00955-8
33
CaoY.SunH.ZhuH.ZhuX.TangX.YanG.et al (2018). Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: A phase I clinical trial. Stem Cell Res. Ther.9 (1), 192. 10.1186/s13287-018-0904-3
34
CastroL. L.KitokoJ. Z.DeboraG.XistoP. C.OlsenH. L. M.Lopes‐PachecoM.et al (2020). Multiple doses of adipose tissue‐derived mesenchymal stromal cells induce immunosuppression in experimental asthma. STEM CELLS Transl. Med.9 (2), 250–260. 10.1002/sctm.19-0120
35
Castro-OropezaR.Vazquez-SantillanK.Díaz-GastelumC.Melendez-ZajglaJ.ZampedriC.Ferat-OsorioE.et al (2020). Adipose-derived mesenchymal stem cells promote the malignant phenotype of cervical cancer. Sci. Rep.10 (1), 14205. 10.1038/s41598-020-69907-x
36
CeccarelliS.PontecorviP.AnastasiadouE.NapoliC.MarcheseC. 2020. “Immunomodulatory effect of adipose-derived stem cells: The cutting edge of clinical application.” Front. Cell Dev. Biol.8 (4): 236. 10.3389/fcell.2020.00236
37
ChenJ-m.HuangQ-y.ZhaoY-x.ChenW-h.LinS.ShiQ-y. 2021a. “The latest developments in immunomodulation of mesenchymal stem cells in the treatment of intrauterine adhesions, both allogeneic and autologous.” Front. Immunol.12 (9): 785717. 10.3389/fimmu.2021.785717
38
ChenL.GuoS.CuiW.LiH.WangH.XuY. (2018). Effect of stem cell transplantation of premature ovarian failure in animal models and patients: A meta-analysis and case report. Exp. Ther. Med. March. 10.3892/etm.2018.5970
39
ChenQ.ShouP. C. Z.JiangM.CaoG.YangQ.CaoJ.et al (2016). Fate decision of mesenchymal stem cells: Adipocytes or osteoblasts?Cell Death Differ.23 (7), 1128–1139. 10.1038/cdd.2015.168
40
ChenX.WangF.HuangZ.WuY.GengJ.WangY. (2021b). Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An update and concise review. Int. J. Med. Sci.18 (13), 2849–2870. 10.7150/ijms.59218
41
ChoK-S.LeeJ-H.ParkM-K.ParkH-K.Hak-SunY.RohH-J. (2015). Prostaglandin E2 and transforming growth factor-β play a critical role in suppression of allergic airway inflammation by adipose-derived stem cells. PLOS ONE10 (7), e0131813. 10.1371/journal.pone.0131813
42
ChowS.LiuJ. (2009). Design and analysis of bioavailability and bioequivalence studies. 3rd ed., 27. Boca Raton: Chapman & Hall/CRC Biostatistics SeriesCRC Press.
43
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015). Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet385 (9980), 1835–1842. 10.1016/S0140-6736(14)61687-1
44
CopelandK. L.JeanetteS.BrownJ. M.CreasmanS. K.LesleeL.SubakD. H. Tet al2012. “Diabetes mellitus and sexual function in middle-aged and older women:” Obstetrics Gynecol.120 (1): 331–340. 10.1097/AOG.0b013e31825ec5fa
45
CorcioneA.FedericaB.FerrettiE.GiuntiD.CappielloV.CazzantiF.et al (2006). Human mesenchymal stem cells modulate B-cell functions. Blood107 (1), 367–372. 10.1182/blood-2005-07-2657
46
CrisostomoP. R.WangY.MarkelT. A.WangM.LahmT.MeldrumD. R. (2008). Human mesenchymal stem cells stimulated by TNF-α, LPS, or hypoxia produce growth factors by an NFκB- but not JNK-dependent mechanism. Am. J. Physiology-Cell Physiology294 (3), C675–C682. 10.1152/ajpcell.00437.2007
47
CuiJ.ShenY.LiR. (2013). Estrogen synthesis and signaling pathways during aging: From periphery to brain. Trends Mol. Med.19 (3), 197–209. 10.1016/j.molmed.2012.12.007
48
CuiL.YinS.LiuW.LiN.ZhangW.CaoY. (2007). Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng.13 (6), 1185–1195. 10.1089/ten.2006.0315
49
DabrowskiF. A.BurdzinskaA.KuleszaA.SladowskaA.ZolocinskaA., (2017). Comparison of the paracrine activity of mesenchymal stem cells derived from human umbilical cord, amniotic membrane and adipose tissue: Paracrine activity of human fetal MSCs. J. Obstetrics Gynaecol. Res.43 (11), 1758–1768. 10.1111/jog.13432
50
DavisS. R.McCloudP.StraussB. J. G.BurgerH. (1995). Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas21 (3), 227–236. 10.1016/0378-5122(94)00898-H
51
DavisS. R.Tran.J. (2001). Testosterone influences libido and well being in women. Trends Endocrinol. Metabolism12 (1), 33–37. 10.1016/S1043-2760(00)00333-7
52
De FranciscisP.MaininiG.MessalliE. M.TrottaC.LuisiA.LaudandoE.et al (2013). Arterial hypertension and female sexual dysfunction in postmenopausal women. Clin. Exp. Obstetrics Gynecol.40 (1), 58–60.
53
de SilvaP. S.O’TooleA.MarcL. G.UlysseC. A.TestaM. A.JulsgaardM.et al (2018). Development of a sexual dysfunction scale for women with inflammatory bowel disease. Inflamm. Bowel Dis.24 (11), 2350–2359. 10.1093/ibd/izy202
54
DelaRosaO.Sánchez-CorreaB.MorgadoS.RamírezC.Borjad.MentaR.et al (2012). Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev.21 (8), 1333–1343. 10.1089/scd.2011.0139
55
DennersteinL.RandolphJ.TaffeJ.DudleyE.BurgerH. 2002. “Hormones, mood, sexuality, and the menopausal transition.” Fertil. Steril.77 (4): 42–48. 10.1016/S0015-0282(02)03001-7
56
Di FrancescoS.CarusoM.RobuffoI.MilitelloA.ToniatoE. (2019). The impact of metabolic syndrome and its components on female sexual dysfunction: A narrative mini-review. Curr. Urol.12 (2), 57–63. 10.1159/000489420
57
DingC.ZouQ.WangF.WuH.ChenR.LvJ.et al (2018a). Human amniotic mesenchymal stem cells improve ovarian function in natural aging through secreting hepatocyte growth factor and epidermal growth factor. Stem Cell Res. Ther.9 (1), 55. 10.1186/s13287-018-0781-9
58
DingL.YanG.WangB.XuL.GuY.TongR.et al (2018b). Transplantation of UC-MSCs on collagen scaffold activates follicles in dormant ovaries of POF patients with long history of infertility. Sci. China Life Sci.61 (12), 1554–1565. 10.1007/s11427-017-9272-2
59
DoumasM.TsiodrasS.TsakirisA.StellaD.ChountaA.PapadopoulosA.et al (2006). Female sexual dysfunction in essential hypertension: A common problem being uncovered. J. Hypertens.24 (12), 2387–2392. 10.1097/01.hjh.0000251898.40002.5b
60
EdessyM.HosniH. N.ShadyY.WafY.BakrS.KamelM. (2016). Autologous stem cells therapy, the first baby of idiopathic premature ovarian failure. Acta Medica Int.3 (1), 19. 10.5530/ami.2016.1.7
61
EljaafariA.PestelJ.Le Magueresse-BattistoniB.ChanonS.WatsonJ.RobertM.et al (2021). Adipose-tissue-derived mesenchymal stem cells mediate PD-L1 overexpression in the white adipose tissue of obese individuals, resulting in T cell dysfunction. Cells10 (10), 2645. 10.3390/cells10102645
62
ElyasiF.KashiZ.TasfiehB.BaharA.KhademlooM. (2015). Sexual dysfunction in women with type 2 diabetes mellitus. Iran. J. Med. Sci.40 (3), 206–213.
63
EngelaA. U.HoogduijnM. J.LitjensN. H. R.BetjesM. G. H.WeimarW.BaanC. C. (2013). Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin. Exp. Immunol.173 (2), 343–354. 10.1111/cei.12120
64
EnzlinP.RosenR.WiegelM.BrownJ.HunterW.GatcombP.et al (2009). Cleary, and the DCCT/EDIC research GroupSexual dysfunction in women with type 1 diabetes. Diabetes Care32 (5), 780–785. 10.2337/dc08-1164
65
EspositoK.CiotolaM.MaiorinoM. I.GiuglianoF.AutorinoR.De SioM.et al (2009). Hyperlipidemia and sexual function in premenopausal women. J. Sex. Med.6 (6), 1696–1703. 10.1111/j.1743-6109.2009.01284.x
66
EvronA.BlumenfeldZ.AdashiE. Y.KolS. (2015). The role of growth factors in ovarian function and development. Glob. Libr. Women’s Med. 10.3843/GLOWM.10288
67
FernándezO.IzquierdoG.FernándezV.LeyvaL.ReyesV.GuerreroM.et al (2018). Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.” edited by tim friede. PLOS ONE13 (5), e0195891. 10.1371/journal.pone.0195891
68
FindlayJ. K.LiewS. H.SimpsonE. R.KorachK. S. (2010). “Estrogen signaling in the regulation of female reproductive functions,” in Fertility control. Editors HabenichtUrsula-F.John AitkenR. (Berlin, Heidelberg: Springer Berlin Heidelberg), 198, 29–35. 10.1007/978-3-642-02062-9_2Handbook of Experimental Pharmacology
69
FischerL. J.StephenM.TulenkoT.GolesorkhiN.ZhangP.LarsonR.et al (2009). Endothelial differentiation of adipose-derived stem cells: Effects of endothelial cell growth supplement and shear force. J. Surg. Res.152 (1), 157–166. 10.1016/j.jss.2008.06.029
70
FouadH.SabryD.ElsetohyK.FathyN. (2016). Therapeutic efficacy of amniotic membrane stem cells and adipose tissue stem cells in rats with chemically induced ovarian failure. J. Adv. Res.7 (2), 233–241. 10.1016/j.jare.2015.05.002
71
FoyC. G.JillC.NewmanD. R.KimmelP. L.WadleyV. G. (2016). Blood pressure, sexual activity, and dysfunction in women with hypertension: Baseline findings from the systolic blood pressure intervention trial (SPRINT). J. Sex. Med.13 (9), 1333–1346. 10.1016/j.jsxm.2016.06.014
72
FranquesaM.MensahF. K.HuizingaR.StriniT.BoonL.LombardoE.DelaRosaO.et al (2015). Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells33 (3), 880–891. 10.1002/stem.1881
73
FraserH. M.MorrisK. D.Wilson.H. (2010). Inhibition of vascular endothelial growth factor during the postovulatory period prevents pregnancy in the marmoset. Contraception82 (6), 572–578. 10.1016/j.contraception.2010.04.020
74
GerberJ. R.JohnsonJ. V.BunnJ. Y.O’BrienS. L. (2005). A longitudinal study of the effects of free testosterone and other psychosocial variables on sexual function during the natural traverse of menopause. Fertil. Steril.83 (3), 643–648. 10.1016/j.fertnstert.2004.08.028
75
GewandterJ.McDermottM. P.HeH.GaoS.CaiX.FarrarJ. T.et al (2019). Demonstrating heterogeneity of treatment effects among patients: An overlooked but important step toward precision medicine. Clin. Pharmacol. Ther.106 (1), 204–210. 10.1002/cpt.1372
76
GiraldiA.Wåhlin-JacobsenS. (2016). Female sexual dysfunction: A call to arms for collaboration to understand the sexological elephant. Nat. Rev. Urol.13 (7), 365–366. 10.1038/nrurol.2016.99
77
GiudiceL. C. (1992). Insulin-like growth factors and ovarian follicular development. Endocr. Rev.13 (4), 641–669. 10.1210/edrv-13-4-641
78
GoldsteinC. E.BrunoG.WeijerC.TaljaardM. (2018). When and how should we cluster and cross over: Methodological and ethical issues. Can. J. Anesthesia/Journal Can. d’anesthésie65 (7), 760–765. 10.1007/s12630-018-1131-1
79
GonzálezM. A.Gonzalez-ReyE.RicoL. (2009). Elena gonzalez–rey, laura rico, dirk büscher, and mario DelgadoAdipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology136 (3), 978–989. 10.1053/j.gastro.2008.11.041
80
Gonzalez-ReyE.GonzalezM. A. N. V.O’ValleF.Hernandez-CortesP.RicoL.BüscherD.et al (2010). Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann. Rheumatic Dis.69 (01), 241–248. 10.1136/ard.2008.101881
81
GospodarowiczD.HughB. (1979). Fibroblast and epidermal growth factors are mitogenic agents for cultured granulosa cells of rodent, porcine, and human origin. Endocrinology104 (3), 757–764. 10.1210/endo-104-3-757
82
GotoH.ShimonoY.FunakoshiY.ImamuraY.ToyodaM.KiyotaN.et al (2019). Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin. Oncogene38 (6), 767–779. 10.1038/s41388-018-0477-8
83
GraciaC. R.FreemanE. W. (2018). Onset of the menopause transition. Obstetrics Gynecol. Clin. N. Am.45 (4), 585–597. 10.1016/j.ogc.2018.07.002
84
GraysonW. L.ZhaoF.IzadpanahR.BunnellB.MaT. (2006). Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. J. Cell. Physiology207 (2), 331–339. 10.1002/jcp.20571
85
GraziottinA.DennersteinL.AlexanderJ. L.GiraldiA.WhippleB. (2006). “Classification, etiology, and key issues in female sexual disorders,” in Standard Practice in sexual medicine. The standards committee of the inte, 305–14. Editors PorstH.BuvatJ. (Oxford, UK: Blackwell Publishing Ltd). 10.1002/9780470755235.ch20
86
GraziottinA.LeiblumS. R. (2005). Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J. Sex. Med.2 (9), 133–145. 10.1111/j.1743-6109.2005.00129.x
87
GraziottinA. (2007). Original research: Prevalence and evaluation of sexual health problems—Hsdd in europe. J. Sex. Med.4 (3), 211–219. 10.1111/j.1743-6109.2007.00447.x
88
GuptaS.LodhaP.KarthickM.TandulwadkarS. (2018). Role of autologous bone marrow-derived stem cell therapy for follicular recruitment in premature ovarian insufficiency: Review of literature and a case report of world’s first baby with ovarian autologous stem cell therapy in a perimenopausal woman of age 45 year. J. Hum. Reproductive Sci.11 (2), 125. 10.4103/jhrs.JHRS_57_18
89
HallJ. M.CouseJ. F.KorachK. S. (2001). The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem.276 (40), 36869–36872. 10.1074/jbc.R100029200
90
HanY-S.LeeJ. H.YoonY. M.YunC. W.NohH. (2016). Hypoxia-induced expression of cellular prion protein improves the therapeutic potential of mesenchymal stem cells. Cell Death Dis.7 (10), e2395. 10.1038/cddis.2016.310
91
HeoJ. S.ChoiY.KimH. O. (2019). Adipose-derived mesenchymal stem cells promote M2 macrophage phenotype through exosomes. Stem Cells Int., 1–10. 10.1155/2019/7921760
92
HerraizS.RomeuM.AnnaB.MartínezS.Díaz-GarcíaC.Gómez-SeguíI.et al (2018). Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil. Steril.110 (3), 496–505. 10.1016/j.fertnstert.2018.04.025
93
HershlagA.SchusterM. W. (2002). Return of fertility after autologous stem cell transplantation. Fertil. Steril.77 (2), 419–421. 10.1016/S0015-0282(01)02987-9
94
HetemäkiN.MikkolaT. S.TikkanenM. J.WangF.HämäläinenE.TurpeinenU.et al2021. “Adipose tissue estrogen production and metabolism in premenopausal women.” J. Steroid Biochem. Mol. Biol.209 (5): 105849. 10.1016/j.jsbmb.2021.105849
95
HillierS. G.WhitelawP. F.SmythC. D. (1994). Follicular oestrogen synthesis: The ‘two-cell, two-gonadotrophin’ model revisited. Mol. Cell. Endocrinol.100 (1–2), 51–54. 10.1016/0303-7207(94)90278-X
96
HoangV. T.PhuongD.HueT.LeM.NguyenT.NguyenT.et al (2020). Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources. Cytotherapy. 10.1016/j.jcyt.2020.09.004
97
IgboeliP.SheikhU.TakalaH.ElSharoudA.McHughA.Gavrilova-JordanL.et al (2020). Intraovarian injection of autologous human mesenchymal stem cells increases estrogen production and reduces menopausal symptoms in women with premature ovarian failure: Two case reports and a review of the literature. J. Med. Case Rep.14 (1), 108. 10.1186/s13256-020-02426-5
98
Ivanova-TodorovaE.BochevI.MourdjevaM.DimitrovR.BukarevD.KyurkchievS.et al (2009). Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol. Lett.126 (1–2), 37–42. 10.1016/j.imlet.2009.07.010
99
JaberH.IssaK.AliE.SalehF. A. (2021). The therapeutic effects of adipose-derived mesenchymal stem cells on obesity and its associated diseases in diet-induced obese mice. Sci. Rep.11 (1), 6291. 10.1038/s41598-021-85917-9
100
JaspersL.FeysF.BramerW. M.FrancoO. H.LeusinkP.EllenT.et al (2016). Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: A systematic review and meta-analysis. JAMA Intern. Med.176 (4), 453. 10.1001/jamainternmed.2015.8565
101
JiaoZ.MaY.ZhangQ.WangY.LiuT.LiuX.et al (2021). The adipose-derived mesenchymal stem cell secretome promotes hepatic regeneration in miniature pigs after liver ischaemia-reperfusion combined with partial resection. Stem Cell Res. Ther.12 (1), 218. 10.1186/s13287-021-02284-y
102
JungJ. W.KwonM.ChoiJ.ShinJ., (2013). Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med. J.54 (5), 1293. 10.3349/ymj.2013.54.5.1293
103
KabatM.BobkovI.KumarS.GrumetM. (2020). Trends in mesenchymal stem cell clinical trials 2004‐2018: Is efficacy optimal in a narrow dose range?STEM CELLS Transl. Med.9 (1), 17–27. 10.1002/sctm.19-0202
104
KasapB.KasapŞ.VatanseverS.KendirciR.OsmanY.ÇalışırM.et al2019. “Effects of adipose and bone marrow-derived mesenchymal stem cells on vaginal atrophy in a rat menopause model.” Gene711 (8): 143937. 10.1016/j.gene.2019.06.027
105
Kawada-HoritaniE.KitaS.OkitaT.NakamuraY.NishidaH.HonmaY.et al (2022). Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade. Diabetologia65 (7), 1185–1197. 10.1007/s00125-022-05708-3
106
KheraM. (2015). Testosterone therapy for female sexual dysfunction. Sex. Med. Rev.3 (3), 137–144. 10.1002/smrj.53
107
KimJ.HemattiP. (2009). Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages. Exp. Hematol.37 (12), 1445–1453. 10.1016/j.exphem.2009.09.004
108
KinghamP. J.KolarM. K.LiudmilaNovikovaNovikovN. L. N.Wiberg.M. (2014). Stimulating the neurotrophic and angiogenic properties of human adipose-derived stem cells enhances nerve repair. Stem Cells Dev.23 (7), 741–754. 10.1089/scd.2013.0396
109
KingsbergS. A.ClaytonA. H. D. P.WilliamsL. A.KropJ.JordanR.LucasJ.et al (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics Gynecol.134 (5), 899–908. 10.1097/AOG.0000000000003500
110
KinnairdT.StabileE.BurnettM. S.LeeC. W.BarrS.FuchsS.et al (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulation Res.94 (5), 678–685. 10.1161/01.RES.0000118601.37875.AC
111
KotM.Baj-KrzyworzekaM.SzatanekR.Musiał-WysockaA.Suda-SzczurekM.MajkaM. (2019). The importance of HLA assessment in ‘off-the-shelf’ allogeneic mesenchymal stem cells based-therapies. Int. J. Mol. Sci.20 (22), 5680. 10.3390/ijms20225680
112
KovalevskyG. (2005). Female sexual dysfunction and use of hormone therapy in postmenopausal women. Seminars Reproductive Med.23 (02), 180–187. 10.1055/s-2005-869486
113
KrakowskyY.GroberE. D. (2018). A practical guide to female sexual dysfunction: An evidence-based review for physicians in Canada. Can. Urological Assoc. J.12 (6), 211–216. 10.5489/cuaj.4907
114
KrawczenkoA.KlimczakA. (2022). Adipose tissue-derived mesenchymal stem/stromal cells and their contribution to angiogenic processes in tissue regeneration. Int. J. Mol. Sci.23 (5), 2425. 10.3390/ijms23052425
115
LanY-W.ChooK-B.ChenC-M.HungT-H.ChenY-B.HsiehC-H.et al (2015). Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res. Ther.6 (1). 10.1186/s13287-015-0081-6
116
Landskroner-EigerS.MonekeI.SessaW. C. (2013). MiRNAs as modulators of angiogenesis. Cold Spring Harb. Perspect. Med.3 (2), a006643. 10.1101/cshperspect.a006643
117
LeeS. Y.ShinJ. E.HwangK.DongH.KimJ. H. (2020). Effect of autologous adipose-derived stromal vascular fraction transplantation on endometrial regeneration in patients of Asherman’s syndrome: A pilot study. Reprod. Sci.27 (2), 561–568. 10.1007/s43032-019-00055-y
118
LiB.ChengL.ZhuM.ZhangY.DuJ.XuY.et al (2017a). Hypoxia-induced mesenchymal stromal cells exhibit an enhanced therapeutic effect on radiation-induced lung injury in mice due to an increased proliferation potential and enhanced antioxidant ability. Cell. Physiology Biochem.44 (4), 1295–1310. 10.1159/000485490
119
LiJ.MaoQ.HeJ.SheH.ZhangZ.YinC. (2017b). Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism. Stem Cell Res. Ther.8 (1), 55. 10.1186/s13287-017-0514-5
120
LiJ.YuQ.HuangH.DengW.CaoX.Adu-FrimpongM.et al (2018). Human chorionic plate-derived mesenchymal stem cells transplantation restores ovarian function in a chemotherapy-induced mouse model of premature ovarian failure. Stem Cell Res. Ther.9 (1), 81. 10.1186/s13287-018-0819-z
121
LiR.LiD.WangH.ChenK.WangS.XuJ.et al (2022). Exosomes from adipose-derived stem cells regulate M1/M2 macrophage phenotypic polarization to promote bone healing via MiR-451a/MIF. Stem Cell Res. Ther.13 (1), 149. 10.1186/s13287-022-02823-1
122
LiaoL.ShiB.ChangH.SuX.ZhangL.BiC.et al (2017). Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics7 (1), 106–116. 10.7150/thno.16911
123
LinG.GarciaM.NingH.BanieL.GuoY-L.LueT. F.et al (2008). Defining stem and progenitor cells within adipose tissue. Stem Cells Dev.17 (6), 1053–1063. 10.1089/scd.2008.0117
124
Linher-MelvilleK.LiJ. (2013). The roles of glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor and nerve growth factor during the final stage of folliculogenesis: A focus on oocyte maturation. REPRODUCTION145 (2), R43–R54. 10.1530/REP-12-0219
125
LodiseN. 2017. “Female sexual dysfunction: A focus on flibanserin.” Int. J. Women’s Health9 (10): 757–767. 10.2147/IJWH.S83747
126
LorenzT. K. (2019). Interactions between inflammation and female sexual desire and arousal function. Curr. Sex. Health Rep.11 (4), 287–299. 10.1007/s11930-019-00218-7
127
MaH.LiuM.LiY.WangW.YangK.LuL.et al (2020). Intrauterine transplantation of autologous menstrual blood stem cells increases endometrial thickness and pregnancy potential in patients with refractory intrauterine adhesion. J. Obstetrics Gynaecol. Res.46 (11), 2347–2355. 10.1111/jog.14449
128
MarędziakM.MaryczK.TomaszewskiK. A.KornickaK.Michael HenryB. (2016). The influence of aging on the regenerative potential of human adipose derived mesenchymal stem cells. Stem Cells Int., 1–15. 10.1155/2016/2152435
129
MartelliV.ValisellaS.MoscatielloS.MatteucciC.LantadillaC.CostantinoA.et al (2012). Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J. Sex. Med.9 (2), 434–441. 10.1111/j.1743-6109.2011.02517.x
130
MashayekhiM.MirzadehE.ChekiniZ.AhmadiF.Eftekhari-YazdiP.VesaliS.et al (2021). Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: Non-randomized clinical trial, phase I, first in human. J. Ovarian Res.14 (1), 5. 10.1186/s13048-020-00743-3
131
MasonA. S. (1976). The events of the menopause. R. Soc. Health J.96 (2), 70–71. 10.1177/146642407609600208
132
MatsushitaK.DzauV. (2017). Mesenchymal stem cells in obesity: Insights for translational applications. Lab. Investig.97 (10), 1158–1166. 10.1038/labinvest.2017.42
133
MattarP.BiebackK. (2015). Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells. Front. Immunol.6 (11). 10.3389/fimmu.2015.00560
134
MayerD.LynchS. E. (2020). Bremelanotide: New drug approved for treating hypoactive sexual desire disorder. Ann. Pharmacother.54 (7), 684–690. 10.1177/1060028019899152
135
McCabeM. P.SharlipI. D.LewisR.AtallaE.BalonR.FisherA. D.et al (2016). Incidence and prevalence of sexual dysfunction in women and men: A consensus statement from the fourth international consultation on sexual medicine 2015. J. Sex. Med.13 (2), 144–152. 10.1016/j.jsxm.2015.12.034
136
McCoyN. L.DavidsonJ. M. (1985). A longitudinal study of the effects of menopause on sexuality. Maturitas7 (3), 203–210. 10.1016/0378-5122(85)90041-6
137
MckinnireyF.HerbertB.GrahamV.McCrackenS. (2021). Immune modulation via adipose derived mesenchymal stem cells is driven by donor sex in vitro. Sci. Rep.11 (1), 12454. 10.1038/s41598-021-91870-4
138
MeliefS. M.Jan ZwagingaJ.FibbeW. E.RoelofsH. (2013). Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl. Med.2 (6), 455–463. 10.5966/sctm.2012-0184
139
MestonC. M. (2003). Validation of the female sexual function index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J. Sex Marital Ther.29 (1), 39–46. 10.1080/713847100
140
MillsE. J.ChanA. W.WuP.VailA.GuyattG. H.AltmanD. G. (2009). Design, analysis, and presentation of crossover trials. Trials10 (1), 27. 10.1186/1745-6215-10-27
141
MinerM.EspositoK.GuayA.MontorsiP.GoldsteinI. (2012). Cardiometabolic risk and female sexual health: The princeton III summary (CME). J. Sex. Med.9 (3), 641–651. 10.1111/j.1743-6109.2012.02649.x
142
MinkinM. (2019). Menopause. Obstetrics Gynecol. Clin. N. Am.46 (3), 501–514. 10.1016/j.ogc.2019.04.008
143
MitchellR.MellowsB.SheardJ.AntonioliM.OliverK.ChambersD.et al (2019). Secretome of adipose-derived mesenchymal stem cells promotes skeletal muscle regeneration through synergistic action of extracellular vesicle cargo and soluble proteins. Stem Cell Res. Ther.10 (1), 116. 10.1186/s13287-019-1213-1
144
MittelbrunnM.Sánchez-MadridF. (2012). Intercellular communication: Diverse structures for exchange of genetic information. Nat. Rev. Mol. Cell Biol.13 (5), 328–335. 10.1038/nrm3335
145
MoerbeekM. (2020). The cluster randomized crossover trial: The effects of attrition in the AB/BA design and how to account for it in sample size calculations. Clin. Trials17 (4), 420–429. 10.1177/1740774520913042
146
MohamedS. A.ShalabyS. M.AbdelazizM.BraktaS.HillW. D.IsmailN.et al (2018). Human mesenchymal stem cells partially reverse infertility in chemotherapy-induced ovarian failure. Reprod. Sci.25 (1), 51–63. 10.1177/1933719117699705
147
MollG.JamesA.Kamhieh-MilzJ., (2019). Intravascular mesenchymal stromal/stem cell therapy product diversification: Time for new clinical guidelines. Trends Mol. Med.25 (2), 149–163. 10.1016/j.molmed.2018.12.006
148
MoravcovaM.MaresJ.HorackovaK. (2022). The Czech version of the utian quality of life scale questionnaire assessing women’s quality of life during menopause. Menopausal Rev.21 (1), 1–9. 10.5114/pm.2021.110833
149
MunirH.WardL. S. C.SheriffL.KembleS.NayarS.BaroneF.et al (2017). Adipogenic differentiation of mesenchymal stem cells alters their immunomodulatory properties in a tissue-specific manner. Stem Cells35 (6), 1636–1646. 10.1002/stem.2622
150
MunkerR.C SchmidJ. A. M.KolbH. J. (2004). An update on graft-versus-host and graft-versus-leukemia reactions: A summary of the sixth international symposium held in schloss ellmau, Germany, january 22–24, 2004. Bone Marrow Transplant.34 (9), 767–780. 10.1038/sj.bmt.1704667
151
MunkerR, R. R.KolbH. J. (2006). Graft-versus-Host and graft-versus-leukemia reactions: A summary of the seventh international symposium held in garmisch-partenkirchen, Germany, february 22nd–25th, 2006, tolerance and immunity, an update on lymphoid malignancies. Bone Marrow Transplant.38 (9), 593–607. 10.1038/sj.bmt.1705499
152
NaJ.KimG. J. (2020). Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: A review. J. Ovarian Res.13 (1), 74. 10.1186/s13048-020-00671-2
153
NajarM.Fayyad-KazanM.MerimiM.MeulemanN.BronD.Fayyad-KazanH.et al (2019). Reciprocal immuno-biological alterations occur during the Co-culture of natural killer cells and adipose tissue-derived mesenchymal stromal cells. Cytotechnology71 (1), 375–388. 10.1007/s10616-019-00294-6
154
NajarM.MelkiR.KhalifeF.LagneauxL.BouhtitF.HassanF.et al2022. “Therapeutic mesenchymal stem/stromal cells: Value, challenges and optimization.” Front. Cell Dev. Biol.9 (1): 716853. 10.3389/fcell.2021.716853
155
NascimentoE. R.MaiaA. C. O.NardiA. E.SilvaA. C. 2015. “Sexual dysfunction in arterial hypertension women: The role of depression and anxiety.” J. Affect. Disord.181 (8): 96–100. 10.1016/j.jad.2015.03.050
156
NasonM.DeanF. (2010). Design and analysis of crossover trials for absorbing binary endpoints. Biometrics66 (3), 958–965. 10.1111/j.1541-0420.2009.01358.x
157
NaumovaI.Castelo-BrancoC. 2018. “Current treatment options for postmenopausal vaginal atrophy.” Int. J. Women’s Health Volume 10 (7): 387–395. 10.2147/IJWH.S158913
158
NelsonH. D. (2008). Menopause. Lancet371 (9614), 760–770. 10.1016/S0140-6736(08)60346-3
159
NgoA. T. L.HangM.LeN.NguyenN.HoangD. M. (2021). Clinically relevant preservation conditions for mesenchymal stem/stromal cells derived from perinatal and adult tissue sources. J. Cell. Mol. Med., 17016. 10.1111/jcmm.17016
160
NguyenL. T.HoangD. M.NguyenK. T.BuiD. M.NguyenH. T.HongT.et al (2021a). Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow‐derived mesenchymal stem/stromal cells. STEM CELLS Transl. Med. June, sctm, 20–0506. 10.1002/sctm.20-0506
161
NguyenT.LiemP.NguyenH. P.HoangD. M. (2021b). Can autologous adipose-derived mesenchymal stem cell transplantation improve sexual function in people with sexual functional deficiency?Stem Cell Rev. Rep. June. 10.1007/s12015-021-10196-w
162
NingH.YangF.JiangM.HuL.FengK.ZhangJ.et al (2008). The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia22 (3), 593–599. 10.1038/sj.leu.2405090
163
NoronhaN.MizukamiA.Caliári-OliveiraC.RochaJ. M.SwiechK.KelenC.et al (2019). Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res. Ther.10 (1), 131. 10.1186/s13287-019-1224-y
164
NowosielskiK.DrosdzolA.AdamS.KowalczykR.SkrzypulecV. (2010). Diabetes mellitus and sexuality—does it really matter?J. Sex. Med.7 (2), 723–735. 10.1111/j.1743-6109.2009.01561.x
165
Ortiz-VirumbralesM.MentaR.PérezL. M. (2020). Ornella Lucchesi, Pablo Mancheño-Corvo, Álvaro Avivar-Valderas, Itziar Palacios, et alHuman Adipose Mesenchymal Stem Cells Modulate Myeloid Cells toward an Anti-Inflammatory and Reparative Phenotype: Role of IL-6 and PGE2. Stem Cell Res. Ther.11 (1), 462. 10.1186/s13287-020-01975-2
166
OwensS. D.AmirK.WalkerN. J.BorjessonD. L. (2016). Allogeneic mesenchymal stem cell treatment induces specific alloantibodies in horses. Stem Cells Int., 1–8. 10.1155/2016/5830103
167
PanésJ.García-OlmoD.Gert Van AsscheJ.ReinischW.BaumgartD. C.DignassA.et al (2018). Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology154 (5), 1334–1342. 10.1053/j.gastro.2017.12.020
168
PanésJ.García-OlmoD.Van AsscheG.ReinischW.BaumgartD. C.DignassA.et al (2016). Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial. Lancet388 (10051), 1281–1290. 10.1016/S0140-6736(16)31203-X
169
PaninaY. A.YakimovA. S.YuliaK.OmlevaA. V.MalinovskayaA. N. S.SalminV. V.et al (2018). Plasticity of adipose tissue-derived stem cells and regulation of angiogenesis. Front. Physiology9 (11), 1656. 10.3389/fphys.2018.01656
170
PeffersM. J.CollinsJ.FangY.Goljanek-WhysallK.RushtonM.LoughlinJ.et al2016. “Age-related changes in mesenchymal stem cells identified using a multi-omics approach.” Eur. Cells Mater.31 (2): 136–159. 10.22203/ecm.v031a10
171
PelusoJ. J.PappalardoA. (1999). Progesterone maintains large rat granulosa cell viability indirectly by stimulating small granulosa cells to synthesize basic fibroblast growth Factor1. Biol. Reproduction60 (2), 290–296. 10.1095/biolreprod60.2.290
172
PengY.ChenX.LiuQ.ZhangX.HuangK.LiuL.et al (2015). Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia29 (3), 636–646. 10.1038/leu.2014.225
173
PezzaniteL. M.FortierL. A.AntczakD. F.JenniferCassanoM.BrosnahanM. M.MillerD.et al (2015). Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo. Stem Cell Res. Ther.6 (1), 54. 10.1186/s13287-015-0053-x
174
PfausJ.GiulianoF.GelezH. 2007. “Bremelanotide: An Overview of preclinical CNS effects on female sexual function.” J. Sex. Med.4 (11): 269–279. 10.1111/j.1743-6109.2007.00610.x
175
PolonioA. M.García-VelascoJ. A.HerraizS. 2021. “Stem cell paracrine signaling for treatment of premature ovarian insufficiency.” Front. Endocrinol.11 (2): 626322. 10.3389/fendo.2020.626322
176
PonceletA. J.VercruysseJ.SaliezA.GianelloP. (2007). Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation83 (6), 783–790. 10.1097/01.tp.0000258649.23081.a3
177
RagniP. L.ColombiniV.LuganoB.de GirolamoB. (2019). Insights into inflammatory priming of adipose-derived mesenchymal stem cells: Validation of extracellular vesicles-embedded MiRNA reference genes as A crucial step for donor selection. Cells8 (4), 369. 10.3390/cells8040369
178
RanganathS. H.LevyO.InamdarM. S.KarpJ. M. (2012). Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell10 (3), 244–258. 10.1016/j.stem.2012.02.005
179
RehmanJ.TraktuevD.LiJ.Merfeld-ClaussS.Temm-GroveC. J.BovenkerkJ. E.et al (2004). Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation109 (10), 1292–1298. 10.1161/01.CIR.0000121425.42966.F1
180
RestouxL. J.DasarirajuS. R.Sharon Van DoornumI. N. A.RomeroL.BriggsA. M. (2020). Systematic review of the impact of inflammatory arthritis on intimate relationships and sexual function. Arthritis Care & Res.72 (1), 41–62. 10.1002/acr.23857
181
RibeiroA.LaranjeiraP.MendesS.VeladaI.LeiteC.AndradeP.et al (2013). Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res. Ther.4 (5), 125. 10.1186/scrt336
182
RosenC.BrownJ.HeimanS.LeibR. (2000). The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther.26 (2), 191–208. 10.1080/009262300278597
183
SabolR. A.GiacomelliP.AdamB.BunnellB. A. (2019). Adipose stem cells and cancer: Concise review. Stem Cells37 (10), 1261–1266. 10.1002/stem.3050
184
SadatS.GehmertS.SongY-H.YenY.BaiX.GaiserS.et al (2007). The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem. Biophysical Res. Commun.363 (3), 674–679. 10.1016/j.bbrc.2007.09.058
185
SamadiP.SakiS.ManoochehriH.SheykhhasanM. (2021). Therapeutic applications of mesenchymal stem cells: A comprehensive review. Curr. Stem Cell Res. Ther.16 (3), 323–353. 10.2174/1574888X15666200914142709
186
SandersJ. E.HawleyJ.LevyW.GooleyT.BucknerC. D.DeegH. J.et al (1996). Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood87 (7), 3045–3052.
187
SarrelP. M. (2002). Androgen deficiency: Menopause and estrogen-related factors. Fertil. Steril.77 (04), 63–67. 10.1016/S0015-0282(02)02967-9
188
SedgwickP. (2014). What is a crossover trial?BMJ348 (1), g3191. 10.1136/bmj.g3191
189
SennS. (2002). “Cross-over trials in clinical research,” in Statistics in Practice. 2nd ed. (Chichester, Eng. ; New York: J. Wiley).
190
ShiY. F.ShaoX. Y.ZhouH. J.ZouJ. Y. (2012). Study on female sexual dysfunction in type 2 diabetic Chinese women. Biomed. Environ. Sci. BES25 (5), 557–561. 10.3967/0895-3988.2012.05.009
191
ShifrenJ. L.BraunsteinG. D.SimonJ. A.CassonP. R.BusterJ. E.RedmondG. P.et al (2000). Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med.343 (10), 682–688. 10.1056/NEJM200009073431002
192
ShifrenJ. L.MonzB. U.RussoP. A.AnthonyS.JohannesC. B. (2008). Sexual problems and distress in United States women: Prevalence and correlates. Obstetrics Gynecol.112 (5), 970–978. 10.1097/AOG.0b013e3181898cdb
193
ShinS.LeeJ.LeeE.ChoiJ.BaeD.ChoiD. (2006). Protective effect of vascular endothelial growth factor (VEGF) in frozen-thawed granulosa cells is mediated by inhibition of apoptosis. Eur. J. Obstetrics Gynecol. Reproductive Biol.125 (2), 233–238. 10.1016/j.ejogrb.2005.10.027
194
SiZ.WangX.SunC.KangY.XuJ.WangX.et al (2019). “Adipose-derived stem cells: Sources, potency, and implications for regenerative therapies.” Biomed. Pharmacother.114 (6), 108765. 10.1016/j.biopha.2019.108765
195
SimonJ. A. 2002. “Estrogen replacement therapy: Effects on the endogenous androgen milieu.” Fertil. Steril.77 (4): 77–82. 10.1016/S0015-0282(02)02986-2
196
SimonJ.KlaiberE.WiitaB.BowenA.YangH. M. (1999). Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause (New York, N.Y.)6 (2), 138–146.
197
SimpsonE.SantenR. J. (2015). Celebrating 75 Years of oestradiol. J. Mol. Endocrinol.55 (3), T1–T20. 10.1530/JME-15-0128
198
SinghN.ShekharB.MohantyS.KumarS.SethT.GirishB. (2020). Autologous bone marrow-derived stem cell therapy for Asherman’s syndrome and endometrial atrophy: A 5-year follow-up study. J. Hum. Reproductive Sci.13 (1), 31. 10.4103/jhrs.JHRS_64_19
199
SongW-J.LiQ.RyuM.AhnJ.DongH.JungY. C.et al (2017). TSG-6 secreted by human adipose tissue-derived mesenchymal stem cells ameliorates DSS-induced colitis by inducing M2 macrophage polarization in mice. Sci. Rep.7 (1), 5187. 10.1038/s41598-017-04766-7
200
SpatzE. S.CanavanM. E.MayurDesaiKrumholzM. H. M.LindauS. T. (2013). Sexual activity and function among middle-aged and older men and women with hypertension. J. Hypertens.31 (6), 1096–1105. 10.1097/HJH.0b013e32835fdefa
201
SteinkampfM. P.MendelsonC. R.SimpsonE. R. (1987). Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. Mol. Endocrinol.1 (7), 465–471. 10.1210/mend-1-7-465
202
StuenkelC. A.DavisS. R.GompelA.LumsdenM. A.HassanM. M.PinkertonJ. V.et al (2015). Treatment of symptoms of the menopause: An endocrine society clinical Practice guideline. J. Clin. Endocrinol. Metabolism100 (11), 3975–4011. 10.1210/jc.2015-2236
203
SturdevantS. G.LumleyT. 2021. “Statistical methods for testing carryover effects: A mixed effects model approach.” Contemp. Clin. Trials Commun.22 (6): 100711. 10.1016/j.conctc.2021.100711
204
SuJ.DingL.ChengJ.YangJ.LiX.YanG.et al (2016). Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency. Hum. Reprod. Oxf. Engl.31 (5), 1075–1086. 10.1093/humrep/dew041
205
SumarwotoT.SurotoH.MahyudinF.TinduhD.NotobrotoH. B.Abdul RantamF.et al2021. “Role of adipose mesenchymal stem cells and secretome in peripheral nerve regeneration.” Ann. Med. Surg.67 (7): 102482. 10.1016/j.amsu.2021.102482
206
SunH.LuJ.LiB.ChenS.XiaoX.WangJ.et al (2018). Partial regeneration of uterine horns in rats through adipose-derived stem cell sheets. Biol. Reproduction99 (5), 1057–1069. 10.1093/biolre/ioy121
207
SunM.WangS.LiY.YuL.GuF.WangC.et al (2013). Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure. Stem Cell Res. Ther.4 (4), 80. 10.1186/scrt231
208
TakahashiA.YousifA.HongL.ChefetzI. (2021). Premature ovarian insufficiency: Pathogenesis and therapeutic potential of mesenchymal stem cell. J. Mol. Med.99 (5), 637–650. 10.1007/s00109-021-02055-5
209
TerracianoP.GarcezT.AyresL.DurliI.BaggioM.Palma KuhlC.et al (2014). Cell therapy for chemically induced ovarian failure in mice. Stem Cells Int.2014, 720753. 10.1155/2014/720753
210
TimmerA.KemptnerD.BauerA.TaksesA.OttC.FürstA. (2008). Determinants of female sexual function in inflammatory bowel disease: A survey based cross-sectional analysis. BMC Gastroenterol.8 (1), 45. 10.1186/1471-230X-8-45
211
TroliceM. P.PappalardoA.PelusoJ. J. (1997). Basic fibroblast growth factor and N-cadherin maintain rat granulosa cell and ovarian surface epithelial cell viability by stimulating the tyrosine phosphorylation of the fibroblast growth factor receptors. Endocrinology138 (1), 107–113. 10.1210/endo.138.1.4836
212
TurturiciG.TinnirelloR.SconzoG.GeraciF. (2014). Extracellular membrane vesicles as a mechanism of cell-to-cell communication: Advantages and disadvantages. Am. J. Physiology-Cell Physiology306 (7), C621–C633. 10.1152/ajpcell.00228.2013
213
UtianW. H.JanataJ. W.KingsbergS. A.SchluchterM.HamiltonJ. C. (2018). The utian quality of life (UQOL) scale: Development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause25 (11), 1224–1231. 10.1097/GME.0000000000001223
214
ValenciaJ.BlancoB.RosaY.VázquezM.Herrero SánchezC.Fernández-GarcíaM.et alConcepción Rodríguez Serrano (2016). Comparative analysis of the immunomodulatory capacities of human bone marrow– and adipose tissue–derived mesenchymal stromal cells from the same donor. Cytotherapy18 (10), 1297–1311. 10.1016/j.jcyt.2016.07.006
215
WangY.YiH.SongY. (2021). The safety of MSC therapy over the past 15 Years: A meta-analysis. Stem Cell Res. Ther.12 (1), 545. 10.1186/s13287-021-02609-x
216
WeiH.ChenQ.LinL.ShaC.LiT.LiuY.et al (2021). Regulation of exosome production and cargo sorting. Int. J. Biol. Sci.17 (1), 163–177. 10.7150/ijbs.53671
217
WellekS.BlettnerM. (2012). On the proper use of the crossover design in clinical trials. Dtsch. Ärzteblatt Int. 10.3238/arztebl.2012.0276
218
WentzensenN.TrabertB. (2015). Hormone therapy: Short-term relief, long-term consequences. Lancet385 (9980), 1806–1808. 10.1016/S0140-6736(14)62458-2
219
WiegelM.MestonC.RosenR. (2005). The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J. Sex Marital Ther.31 (1), 1–20. 10.1080/00926230590475206
220
Writing Group for the Women’s Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA J. Am. Med. Assoc.288 (3), 321–333. 10.1001/jama.288.3.321
221
WulffC.WiegandS. J.SaundersP. T. K.ScobieG. A.FraserH. M. (2001). Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated flt-1-fc (vascular endothelial growth factor TrapA40). Endocrinology142 (7), 3244–3254. 10.1210/endo.142.7.8258
222
YanL.WuY.LiL.WuJ.ZhaoF.GaoZ.et al (2020). Clinical analysis of human umbilical cord mesenchymal stem cell allotransplantation in patients with premature ovarian insufficiency. Cell Prolif.53 (12). 10.1111/cpr.12938
223
YañezR.AlbertoO.AldeaM.BuerenJ. A.LamanaM. L. (2010). Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp. Cell Res.316 (19), 3109–3123. 10.1016/j.yexcr.2010.08.008
224
YañezR.Luisa LamanaM.García‐CastroJ.ColmeneroI.RamírezM.JuanA. B. (2006). Adipose tissue‐derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft‐versus‐host disease. STEM CELLS24 (11), 2582–2591. 10.1634/stemcells.2006-0228
225
YangC.LuoL.BaiX.ShenK.LiuK.WangJ.et al2020. “Highly-expressed MicoRNA-21 in adipose derived stem cell exosomes can enhance the migration and proliferation of the HaCaT cells by increasing the MMP-9 expression through the PI3K/AKT pathway.” Archives Biochem. Biophysics681 (3): 108259. 10.1016/j.abb.2020.108259
226
YangC-Y.ChangP-Y.ChenJ-Y.WuB-S.YangA-H.LeeO. K-S. (2021). Adipose-derived mesenchymal stem cells attenuate dialysis-induced peritoneal fibrosis by modulating macrophage polarization via interleukin-6. Stem Cell Res. Ther.12 (1), 193. 10.1186/s13287-021-02270-4
227
YangY-H. K. (2018). Aging of mesenchymal stem cells: Implication in regenerative medicine. Regen. Ther.9 (12), 120–122. 10.1016/J.RETH.2018.09.002
228
YuanY.NiS.ZhugeA.LiL.LiB. 2022. “Adipose-derived mesenchymal stem cells reprogram M1 macrophage metabolism via PHD2/HIF-1α pathway in colitis mice.” Front. Immunol.13 (6): 859806. 10.3389/fimmu.2022.859806
229
ZazaR.JamaliF.HassounehM.AlhattabD.AlAlawiS.AwidiA. (2019). Adipose tissue derived mesenchymal stem cells exhibit a superior immune-modulatoery effect on mature dendritic cells compared to bone marrow derived mesenchymal stem cells. Cytotherapy21 (5), e11. 10.1016/j.jcyt.2019.04.036
230
ZhangH.LuoQ.LuX.YinN.ZhouD.ZhangL.et al (2018). Effects of HPMSCs on granulosa cell apoptosis and AMH expression and their role in the restoration of ovary function in premature ovarian failure mice. Stem Cell Res. Ther.9 (1), 20. 10.1186/s13287-017-0745-5
231
ZhangJ.NieJ.ZouM.ZengQ.YueF.LuoZ.et al (2022). Prevalence and associated factors of sexual dysfunction in patients with inflammatory bowel disease. Front. Endocrinol.13 (04), 881485. 10.3389/fendo.2022.881485
232
ZhangY.LiuY.LiuH.TangW. H. (2019). Exosomes: Biogenesis, biologic function and clinical potential. Cell & Biosci.9 (1), 19. 10.1186/s13578-019-0282-2
233
ZhangY.MaY.ChenJ.WangM.YuanC.LiL.et al (2021). Mesenchymal stem cell transplantation for vaginal repair in an ovariectomized rhesus macaque model. Stem Cell Res. Ther.12 (1), 406. 10.1186/s13287-021-02488-2
234
ZhangY.NowickaA.SolleyT. N.WeiC.ParikhA.CourtL.et al (2015). Stromal cells derived from visceral and obese adipose tissue promote growth of ovarian cancers.” edited by sandra orsulic. PLOS ONE10 (8), e0136361. 10.1371/journal.pone.0136361
235
ZhaoY.SuP.HuangF.ShiQ.LinS.2019). Using mesenchymal stem cells to treat female infertility: An update on female reproductive diseases. Stem Cells Int., 1–10. 10.1155/2019/9071720
236
ZhengG.QiuG.GeM.HeJ.HuangL.ChenP.et al (2017). Human adipose-derived mesenchymal stem cells alleviate obliterative bronchiolitis in a murine model via Ido. Respir. Res.18 (1), 119. 10.1186/s12931-017-0599-5
237
ZhouP.BaumgartenS. C.WuY.BennettJ.WinstonN.Hirshfeld-CytronJ.et al (2013). IGF-I signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells. Mol. Endocrinol.27 (3), 511–523. 10.1210/me.2012-1307
Summary
Keywords
sexual function impairment, female sexual dysfunction, adipose-derived mesenchymal stem cells, cell therapy, regenerative medicine, menopause, ASCs (adipose stem cells)
Citation
Hoang VT, Nguyen H-P, Nguyen VN, Hoang DM, Nguyen T-ST and Nguyen Thanh L (2022) “Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial”. Front. Cell Dev. Biol. 10:956274. doi: 10.3389/fcell.2022.956274
Received
30 May 2022
Accepted
29 July 2022
Published
28 September 2022
Volume
10 - 2022
Edited by
Drenka Trivanović, University Hospital Würzburg, Germany
Reviewed by
Ivana Drvenica, University of Belgrade, Serbia
Malgorzata Witkowska-Zimny, Medical University of Warsaw, Poland
Ekaterina Vachkova, Trakia University, Bulgaria
Updates
Copyright
© 2022 Hoang, Nguyen, Nguyen, Hoang, Nguyen and Nguyen Thanh.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Liem Nguyen Thanh, v.liemnt@vinmec.com
This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.